profit from every $100 of sales.
$0$100
Synaptogenix
We have no price for Synaptogenix since 27 April 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$24.55+0.00% today
-23.1% since Dec 15, 25
1-year low $20.701-year high $43.54
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Synaptogenix vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Synaptogenix | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Synaptogenix's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- 0.00
- 0.5×
- 71.2×
- –
- –
- -58,615.6%
- -241.9%
- 0.0%
Profitability
- 100.0%
- -3,259.2%
- -9,609.2%
- -3,024.0%
- -40.6%
- -80.6%
- -182.5%
- -111.2%
- -40.6%
- 107.7%
Growth
- –
- –
- −130,838.3%
- –
- +101.5%
Financial health
- -0.6×
- 0.00
- 0.0%
- –
- 13.99
- 13.99
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 8%of 963
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Nov 14, 2025 | -1.56 | – | – |
| Aug 13, 2025 | -1.18 | – | – |
| May 15, 2025 | 0.04 | – | – |
| Mar 27, 2025 | -4.36 | -2.06 | −111.7% |
| Nov 12, 2024 | -4.58 | -1.95 | −134.9% |
| Aug 14, 2024 | -1.18 | -1.83 | +35.5% |
| May 15, 2024 | -0.41 | – | – |
| Apr 1, 2024 | 0.63 | -9.50 | +106.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
80Pass
Philip Fisher
53No pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
49No pass
Terry Smith
45No pass
Questions about Synaptogenix
Is Synaptogenix a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Synaptogenix AI analysis
What does Synaptogenix do?
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is in Biotechnology.
Does Synaptogenix pay a dividend?
No. Synaptogenix does not pay a dividend at the moment.
Who are Synaptogenix's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Synaptogenix's.
Prices: daily closes to Apr 27, 2026. Fundamentals: company reports via invest-like data.